Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Pediatric Oncology

Your Child's Diagnosis: Finding Your Footing

At a Glance

Medulloblastoma is the most common cancerous pediatric brain tumor, starting in the cerebellum. It is highly treatable, with a standard-risk 5-year survival rate of over 80%. Modern care tests for specific molecular subgroups to personalize treatment and protect long-term brain development.

The moment you hear the words “brain tumor,” the world shifts. It is a diagnosis that carries a level of terror few can imagine. If you feel overwhelmed, paralyzed, or unable to process the details, please know that these are natural responses to an extraordinary situation. Your primary job right now is simply to be there for your child. The medical team is there to handle the science [1].

What is Medulloblastoma?

Medulloblastoma is a fast-growing embryonal tumor, meaning it begins in “primitive” cells that were meant to develop into mature brain cells but instead grew out of control [1]. It starts in the cerebellum, the part of the brain at the lower back of the skull (the posterior fossa) that controls balance and coordination [1][2].

While medulloblastoma is the most common malignant (cancerous) brain tumor in children—accounting for about 20% of all pediatric brain tumors—it can also occur in adults, though it is much rarer in grown-ups [3][4].

Three Stabilizing Facts

In the first few days of diagnosis, information can feel like a blur. These three facts represent the current reality of medulloblastoma care and can help provide a sense of orientation:

  1. High Survival in the Modern Era: While this is a serious diagnosis, it is also a highly treatable one. For children in the “standard-risk” category, 5-year survival rates are now approximately 80% or higher [5][6].
  2. Precision Treatment (Not “One Size Fits All”): Since 2021, the medical world has moved away from treating all medulloblastomas the same way [7]. Your child’s tumor will be tested for its molecular subgroup (WNT, SHH, Group 3, or Group 4). This allows doctors to tailor treatment specifically to the biology of your child’s tumor—ensuring they get exactly the right amount of care they need [8][9].
  3. Advanced Protective Technology: Modern treatments are designed not just to cure the cancer, but to protect your child’s future. Tools like Proton Beam Therapy and specialized chemotherapy protocols are significantly better at sparing healthy brain tissue than the treatments used only a decade ago, helping to preserve a child’s learning and memory abilities [10][11].

The Road Ahead

Medulloblastoma is no longer a single mystery; it is a well-mapped disease with highly standardized protocols [12]. You are entering a world of “multidisciplinary care,” where neurosurgeons, oncologists, and specialized nurses work together toward a shared goal: a cure with the highest possible quality of life [13][14].

In the coming days, you will hear a lot of new terminology. Take it one conversation at a time. Your child’s care team is your partner in this, and every question you ask is a step toward regaining a sense of control.

Common questions in this guide

What is a medulloblastoma?
Medulloblastoma is a fast-growing embryonal tumor that starts in the cerebellum, the lower back part of the brain that controls balance and coordination. It is the most common malignant brain tumor found in children.
What is the survival rate for childhood medulloblastoma?
Medulloblastoma is a highly treatable diagnosis. For children whose tumors are in the standard-risk category, current five-year survival rates are 80 percent or higher.
What are medulloblastoma molecular subgroups?
Doctors categorize these tumors into four subgroups called WNT, SHH, Group 3, and Group 4. Knowing the exact subgroup allows the oncology team to tailor therapy to the specific biology of your child's tumor, avoiding a one-size-fits-all approach.
Why is proton beam therapy used to treat medulloblastoma?
Proton beam therapy is an advanced radiation treatment designed to cure cancer while minimizing damage to surrounding healthy brain tissue. This precision helps protect a child's cognitive abilities, learning, and memory as they grow.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's molecular subgroup (WNT, SHH, Group 3, or Group 4), and how does this affect their treatment plan?
  2. 2.What is my child's risk category (standard-risk or high-risk)?
  3. 3.Does this hospital follow the latest 2021 WHO classification protocols for diagnosis?
  4. 4.How many children with medulloblastoma has your team treated in the last year?
  5. 5.Is proton beam therapy an option for my child, and if not, where is the nearest center that offers it?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Arrested development: the dysfunctional life history of medulloblastoma.

    Tao R, Han K, Wu SC, et al.

    Genes & development 2025; (39(1-2)):4-17 doi:10.1101/gad.351936.124.

    PMID: 39231614
  2. 2

    Incidence, Trends, and Survival of Children With Embryonal Tumors.

    Tulla M, Berthold F, Graf N, et al.

    Pediatrics 2015; (136(3)):e623-32 doi:10.1542/peds.2015-0224.

    PMID: 26304823
  3. 3

    Molecular Proteomic Characterization of a Pediatric Medulloblastoma Xenograft.

    Tsangaris GT, Dimas K, Malamou A, et al.

    Cancer genomics & proteomics 2017; (14(4)):267-275 doi:10.21873/cgp.20037.

    PMID: 28647700
  4. 4

    Adult Medulloblastoma: Updates on Current Management and Future Perspectives.

    Franceschi E, Giannini C, Furtner J, et al.

    Cancers 2022; (14(15)) doi:10.3390/cancers14153708.

    PMID: 35954372
  5. 5

    Overview and recent advances in the targeting of medulloblastoma cancer stem cells.

    Paul MR, Zage PE

    Expert review of anticancer therapy 2021; (21(9)):957-974 doi:10.1080/14737140.2021.1932472.

    PMID: 34047251
  6. 6

    Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients.

    Gottardo NG, Gajjar A

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(24)):4996-4998 doi:10.1158/1078-0432.CCR-23-2331.

    PMID: 37823794
  7. 7

    Spinal Ependymomas: An Updated WHO Classification and a Narrative Review.

    Villanueva-Castro E, Meraz-Soto JM, Hernández-Dehesa IA, et al.

    Cureus 2023; (15(11)):e49086 doi:10.7759/cureus.49086.

    PMID: 38125233
  8. 8

    Genome-wide methylation and copy number variation analysis of medulloblastoma in a Saudi Arabian pediatric population.

    AlKofide A, Arabi T, Ahmed AA, et al.

    Annals of medicine and surgery (2012) 2025; (87(10)):6265-6271 doi:10.1097/MS9.0000000000003643.

    PMID: 41199913
  9. 9

    New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma.

    Fang FY, Rosenblum JS, Ho WS, Heiss JD

    Cancers 2022; (14(9)) doi:10.3390/cancers14092285.

    PMID: 35565414
  10. 10

    Systematic Review and Meta-Analysis of Proton Beam Therapy Versus Photon Radiotherapy for Medulloblastoma: TRP-Medulloblastoma 2025.

    Li Y, Mizumoto M, Oshiro Y, et al.

    Cancers 2025; (17(13)) doi:10.3390/cancers17132191.

    PMID: 40647489
  11. 11

    Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only.

    Kahalley LS, Douglas Ris M, Mahajan A, et al.

    Neuro-oncology 2019; (21(6)):809-818 doi:10.1093/neuonc/noz041.

    PMID: 30753584
  12. 12

    Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

    Robinson GW, Rudneva VA, Buchhalter I, et al.

    The Lancet. Oncology 2018; (19(6)):768-784 doi:10.1016/S1470-2045(18)30204-3.

    PMID: 29778738
  13. 13

    Evolution of neurosurgical advances and nuances in medulloblastoma therapy.

    Rechberger JS, Power EA, DeCuypere M, Daniels DJ

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(4)):1031-1044 doi:10.1007/s00381-023-06239-x.

    PMID: 38112693
  14. 14

    Late effects of medulloblastoma treatment: multidisciplinary approach of survivors.

    Aktekin EH, Kütük MÖ, Sangün Ö, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(2)):417-425 doi:10.1007/s00381-023-06146-1.

    PMID: 37698649

This page provides introductory information about medulloblastoma for educational purposes. Always consult your pediatric neuro-oncology team for medical advice tailored to your child's specific tumor subgroup and condition.

Get notified when new evidence is published on Medulloblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.